Table 2.
Severe adverse events (AEs) in patients with SARS-CoV-2 pneumonia receiving remdesivir.
Event | Total n = 35 | ICU n = 18 | IDWn = 17 |
---|---|---|---|
Reported grade 2−3 AEs | |||
Hypertransaminasemia | 15 (42.8 %) | 8 (44.4 %) | 7 (41.2 %) |
Increased total bilirubin levels | 7 (20.0 %) | 2 (11.1 %) | 5 (29.4 %) |
Acute kidney injury | 8 (22.8 %) | 7 (38.8 %) | 1 (5.9 %) |
Rash | 2 (5.7 %) | – | 2 (11.8 %) |
Any AE leading to treatment discontinuation | 8 (22.8 %) | 6 (33.3 %) | 2 (11.7 %) |